Gros Priti, Garcia Laura Armengou, Fox Susan H
Edmond J. Safra Program in Parkinson's Disease, Movement Disorders Clinic, Krembil Brain Institute, UHN Toronto Western Hospital, 399 Bathurst Street MC7 421, Toronto, Ontario M5T 2S8, Canada; Institute of Health Policy, Management and Evaluation, Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario, Canada.
Edmond J. Safra Program in Parkinson's Disease, Movement Disorders Clinic, Krembil Brain Institute, UHN Toronto Western Hospital, 399 Bathurst Street MC7 421, Toronto, Ontario M5T 2S8, Canada.
Neurol Clin. 2025 May;43(2):399-426. doi: 10.1016/j.ncl.2024.12.013. Epub 2025 Jan 22.
The prevalence and burden of Parkinson's disease (PD) is rising. Motor symptoms are primarily treated with dopamine replacement, although with limitations and complications over time. Advances in PD research include new drug candidates and innovative repurposing of existing drugs targeting various molecular mechanisms. Several agents are under Food and Drug Administration review, highlighting the dynamic progress in the field. This review summarizes the latest experimental therapies for PD, including both motor and nonmotor symptom treatments. A total of 147 studies were included, examining new dopaminergic and nondopaminergic therapies, innovative drug formulations, and approaches to managing motor complications and nonmotor symptoms.
帕金森病（PD）的患病率和负担正在上升。运动症状主要通过多巴胺替代疗法进行治疗，不过随着时间推移存在局限性和并发症。PD研究的进展包括新的候选药物以及针对各种分子机制对现有药物进行创新性重新利用。几种药物正在接受美国食品药品监督管理局的审查，凸显了该领域的动态进展。本综述总结了PD的最新实验性疗法，包括运动症状和非运动症状的治疗。总共纳入了147项研究，这些研究考察了新的多巴胺能和非多巴胺能疗法、创新药物剂型以及处理运动并发症和非运动症状的方法。
